Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 6:34 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 12,225 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multiple Diseases Clear all

Conditions: Schizophrenia, Mental Disorder, Nervous System Diseases
Interventions: Aripiprazole, OPC-14597; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 11
States / cities: Cerritos, California • Garden Grove, California • San Diego, California + 8 more

Conditions: ADPKD
Interventions: Spironolactone, Sugar pill; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 20 Years to 55 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Spinal Deformity
Interventions: Not listed
Lead sponsor: International Spine Study Group Foundation; Other
Eligibility: 18 Years and older
Enrollment: 1,999 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2026
U.S. locations: 9
States / cities: La Jolla, California • Sacramento, California • San Francisco, California + 5 more

Conditions: Healthy Volunteers
Interventions: Placebo, PF-06427878; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Glendale, California • South Miami, Florida

Conditions: Congenital Bleeding Disorder, Congenital FXIII Deficiency
Interventions: catridecacog; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 7
States / cities: Orange, California • Tampa, Florida • Atlanta, Georgia + 4 more

Conditions: Autologous Stem Cell Transplantation
Interventions: G-CSF plus plerixafor; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 78 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 8
States / cities: Duarte, California • Tampa, Florida • Atlanta, Georgia + 5 more

Conditions: Multiple Myeloma, Primary Amyloidosis
Interventions: Melphalan, Stem Cell Infusion, Questionnaires, Granulocyte-colony stimulating factor (G-CSF), Apheresis; Drug · Procedure · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 60 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Carotid Stenosis, Ischemic Stroke, Transient Ischemic Attack
Interventions: intensive medical therapy; Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 40 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 11
States / cities: Hartford, Connecticut • Atlanta, Georgia • Chicago, Illinois + 7 more

Conditions: Severe Hepatic Veno-Occlusive Disease
Interventions: Defibrotide; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: Not listed
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 22
States / cities: Duarte, California • Palo Alto, California • Denver, Colorado + 19 more

Conditions: Opioid Induced Constipation
Interventions: Polyethylene Glycol 3350, Movantik; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 84 Years
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 53
States / cities: Huntsville, Alabama • Phoenix, Arizona • Anaheim, California + 46 more

Conditions: Solid Tumor, Advanced Solid Tumor, Non Small Cell Lung Cancer, Colo-rectal Cancer
Interventions: MRTX0902, MRTX849; Drug
Lead sponsor: Mirati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 17
States / cities: New Haven, Connecticut • Newark, Delaware • Orlando, Florida + 13 more

Conditions: Multiple Sclerosis (MS) - Relapsing-remitting
Interventions: Ublituximab, Other disease modifying therapies; Drug · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Solid Tumors, ER+ Breast Cancer, Triple Negative Breast Cancer, TNBC, ARID1A Gene Mutation, Small Cell Lung Cancer, SCLC
Interventions: JAB-2485 (Aurora A inhibitor); Drug
Lead sponsor: Jacobio Pharmaceuticals Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: Detroit, Michigan • St Louis, Missouri • Dallas, Texas + 1 more

Conditions: Neovascular Age Related Macular Degeneration
Interventions: Physician-guided diagnostic; Procedure
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 5
States / cities: Bel Air, Maryland • Bethesda, Maryland • Columbia, Maryland + 2 more

Conditions: Atopic Dermatitis
Interventions: ASLAN004, ASLAN004 Placebo; Drug
Lead sponsor: ASLAN Pharmaceuticals; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 5
States / cities: Fremont, California • Los Angeles, California • Miami, Florida + 2 more

Conditions: Multiple Myeloma, Non-Hodgkin's Lymphoma
Interventions: Meloxicam, Filgrastim; Drug
Lead sponsor: Sherif S. Farag; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Hepatic Impairment, NASH - Nonalcoholic Steatohepatitis, Cirrhosis, Liver
Interventions: MGL-3196; Drug
Lead sponsor: Madrigal Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 87 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 3
States / cities: Orlando, Florida • Saint Paul, Minnesota • San Antonio, Texas

Conditions: Solid Tumor, Adult
Interventions: DF9001, KEYTRUDA® (pembrolizumab); Drug
Lead sponsor: Dragonfly Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 17
States / cities: Gilbert, Arizona • Phoenix, Arizona • Irvine, California + 14 more

Conditions: Ulcerative Colitis
Interventions: BI 3032950 intravenous (Part A), BI 3032950 subcutaneous (Part B); Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 14
States / cities: Scottsdale, Arizona • Colorado Springs, Colorado • Kissimmee, Florida + 10 more

Conditions: Multiple Myeloma
Interventions: Daratumumab IV, Lenalidomide, Dexamethasone, Daratumumab SC; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 737 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 83
States / cities: Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 80 more

Conditions: Advanced Cancer, Gastric Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer Metastatic, Colo-rectal Cancer, Solid Tumor, Solid Carcinoma, Solid Carcinoma of Stomach, Cancer of Stomach
Interventions: Minnelide™Capsules; Drug
Lead sponsor: Minneamrita Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 7
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 4 more

Conditions: Diphtheria, Tetanus, Acellular Pertussis
Interventions: Combined diphtheria, tetanus, acellular pertussis vaccine; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 10 Years to 18 Years
Enrollment: 4,116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2004
U.S. locations: 44
States / cities: Mesa, Arizona • Tempe, Arizona • Jonesboro, Arkansas + 39 more

Conditions: Hypertension, Hypercholesterolemia, Dyslipidemia
Interventions: Valsartan and simvastatin; Drug
Lead sponsor: Novartis; Industry
Eligibility: 50 Years and older
Enrollment: 412 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Healthy Subjects, Osteoarthritis
Interventions: AGG-523; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 40 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Safety and Tolerability Study of Aripiprazole IM Depot in Adult Subjects With Schizophrenia

Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Prospective, Multi-Center Adult Spinal Deformity Outcomes Database Registry

A Multiple Dose Safety And Pharmacokinetic (PK) Study Of PF-06427878 In Overweight-Obese, Otherwise Healthy Subjects

Use of rFXIII in Treatment of Congenital FXIII Deficiency, a Prospective Multi-centre Observational Study

AMD3100 (Plerixafor) With G-CSF in Poor Mobilizing Adult Patients Who Previously Failed Hematopoietic Stem Cell (HSC) Collection/Attempts

Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden

Symptomatic Carotid Outcomes Registry

Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients

To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced Constipation

A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway

Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis

JAB-2485 Activity in Adult Patients With Advanced Solid Tumors

NVAMD Satellite Study

A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis

A Phase II Trial Using Meloxicam Plus Filgrastim in Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma

Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects

Study of DF9001 in Patients With Advanced Solid Tumors

A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis

Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma

A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors

A Combined Tdap Vaccine Used As A Booster Compared To Licensed Td Vaccine

Efficacy and Safety of Valsartan and the Combination of Valsartan and Simvastatin

Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses in Healthy